- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03182816
CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor
A Clinical Study of CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for Patients With EGFR Positive Advanced Solid Tumors
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study will be conducted using a phase I/II trial design to assess the efficacy and safety of the CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T for patients with EGFR positive advanced recurrent or refractory malignant solid tumors. EGFR-CAR-T can specificly and effectively kill the EGFR positive cancer cells, CTLA-4 and PD-1 antibodies are secreted from the CAR-T cells could improve immunosuppression microenvironment, new CAR-T cells contain the advantages of CAR-T and immune checkpoint inhibitor, which is a promising therapeutic method for advanced solid tumors.
The new CAR-T therapy is applied to clinical practice as bellow. T cells are prepared from peripheral blood mononuclear cells (PBMC) by leukapheresis, then activated and engineered to express CTLA-4 and PD-1 antibodies and chimeric antigen receptor targeting EGFR. Cells are proliferated in culture and returned to the patients by venous transfusion therapy. A total of 40 patients may be enrolled in the study. The total duration of the study is expected to be approximately 24 months.
Study Type
Enrollment (Anticipated)
Phase
- Phase 2
- Phase 1
Contacts and Locations
Study Contact
- Name: Zhiwei Zhang, Ph.D
- Phone Number: 0086-021-39595338
- Email: zhangzw@shcell.com
Study Locations
-
-
Zhejiang
-
Ningbo, Zhejiang, China, 315201
- Recruiting
- Ningbo No.5 Hospital (Ningbo Cancer Hospital)
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with relapsed or refractory advanced solid malignancies (diagnosed by histology or cytology detection).
- Progressive disease and no response after at least second-line therapy.
- Gender unlimited, age from 18 years to 80 years.
- Life expectancy ≥3 months.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0-2.
- Adequate venous access for peripheral blood mononuclear cell (PBMC) apheresis, and no other contraindications.
- Immunohistochemistry (IHC) score of EGFR on tumor tissue ≥1+.
- Adequate hepatic function, renal function and bone marrow function (withhin 7 days before enrollment): white blood cell (WBC) ≥3.0×10^9/L; platelet ≥100×10^9/L; hemoglobin ≥90 g/L; lymphocyte ≥0.7×10^9/L; total bilirubin ≤2 times the upper limit of the normal value; alanine aminotransferase and aspartate transaminase(ALT and AST) ≤2.5 times the upper limit of the normal value; serum creatinine ≤1.5 times the upper limit of the normal value.
- There is no other treatments (chemotherapy, radiotherapy, etc.) within four weeks before enrollment.
- There is at least one measurable tumor lesion.
- Patients have adequate ability to understand, sign informed consents and take part in the clinical research voluntarily.
- Female patients in child bearing period must have evidence of negative pregnancy test, and agree to take effective contraceptive measures until 4 months after cells infusion.
Exclusion Criteria:
- Patients with two or more kinds of tumors.
- Patients with active viral or bacterial infection, and have failed to be controlled by anti-infective treatment.
- Patients with seropositive reponse of Human immunodeficiency virus (HIV) and syphilis, or fail to control the hepatitis B virus or hepatitis C virus infection.
- Patients with active rheumatic diseases, organ transplantation and other diseases affecting the immune system seriously.
- Patients with severe heart and lung dysfunction.
- Patients with severe chronic diseases of kidney, liver and other important organs.
- Patients with any other serious illnesse that the investigators consider it will may affect the patient's treatments, follow-up or assessment, including any uncontrolled clinically significant neurological or psychiatric disorders, immunoregulatory diseases, metabolic diseases, infectious diseases and so on.
- Patients who take part in clinical trials of other drugs or biological therapy at present or within 30 days before enrollment.
- Patients who need long-term use of immunosuppressive drugs or patients who are undergoing treatment of autoimmune diseases.
- Patients who need long-term use of glucocorticoid.
- Women patients in gestation period or suckling period.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: anti-CTLA-4/PD-1 expressing EGFR-CAR-T
This study have only one arm that is anti-CTLA-4/PD-1 expressing EGFR-CAR-T group.
All patients with advanced solid tumor will take part in the screening, who matching all the conditions will be chosen for the treatment using CTLA-4 and PD-1 antibodies expressing EGFR-targeted CAR-T cells.
New CAR-T cells are cultured from PBMC and returned to the patients by venous transfusion.
|
Every cycle, peripheral blood mononuclear cells (PBMC) are collected on day 0, CAR-T cells are cultured in a GMP standard workshop.
Patients are given a three-day regimen of chemotherapy consisting of cyclophosphamide aimed to deplete the lymphocytes before cells infusion.
Then the patients will receive an i.v.gtt infusion of CTLA-4 and PD-1 antibodies expressing EGFR-CAR-T cells at (2-5) ×10^7 cells/kg from day 18 to day 19 (±2 days). 2 cycles are regarded as a treatment period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of treatment-related adverse events as assessed by CTCAE v4.0
Time Frame: 2 years
|
Determine treatment-related adverse events of the immunotherapy with common toxicity criteria for adverse effects (CTCAE) version 4.0.
|
2 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The response evaluation of of the treatment for advanced solid tumors
Time Frame: 2 years
|
The efficacy of the treatment is assessed according to the response evaluation criteria in solid tumor version 1.1 (RECIST1.1),
which is defined as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).
|
2 years
|
Progression free survival
Time Frame: 2 years
|
Progression free survival is defined as the time from the day in which the patient is enrolled to the date on which tumor progresses or the date on which the patient dies for any cause.
|
2 years
|
Overall survival
Time Frame: 2 years
|
Overall survival is defined as the time from the day in which the patient is enrolled to the date on which the patient dies for any cause.
|
2 years
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The quality of life as assessed by EORTC QLQ-30
Time Frame: 2 years
|
The quality of life is assessed before and after the treatment by EORTC QLQ-30.
|
2 years
|
Proliferation and persistence of EGFR-CAR-T cells in peripheral blood
Time Frame: 6 months
|
CAR-T proportion in peripheral blood of the patients is detected by flow cytometry assay to study the proliferation and persistence of EGFR specific CAR-T cells.
|
6 months
|
CTLA-4 and PD-1 antibodies level in peripheral blood
Time Frame: 6 months
|
CTLA-4 and PD-1 antibodies level are detected by ELISA assay to asess the expressing level of CTLA4 and PD-1 antibodies from CAR-T cells.
|
6 months
|
Collaborators and Investigators
Publications and helpful links
Study record dates
Study Major Dates
Study Start (ANTICIPATED)
Primary Completion (ANTICIPATED)
Study Completion (ANTICIPATED)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ACTUAL)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- H2017-03-P01
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Advanced Solid Tumor
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Pyxis Oncology, IncRecruiting
-
Neurogene Inc.Merck Sharp & Dohme LLCActive, not recruitingSolid Tumor | Advanced Solid TumorUnited States, Australia, Canada
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyCompletedSolid Tumor | Advanced Solid TumorSpain, United States, Netherlands, United Kingdom
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesChina
-
Zhuhai Yufan Biotechnologies Co., LtdRecruitingAdvanced Solid Tumor | Advanced Solid MalignanciesUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia
-
Jazz PharmaceuticalsMerck Sharp & Dohme LLCRecruitingAdvanced Solid Tumor | Metastatic Solid TumorUnited States
-
PharmaEngineNot yet recruitingAdvanced Solid Tumor | Metastatic Solid Tumor
Clinical Trials on anti-CTLA-4/PD-1 expressing EGFR-CAR-T
-
Shanghai Cell Therapy Research InstituteUnknownAdvanced Solid TumorChina
-
Shanghai Cell Therapy Research InstituteUnknownAdvanced Solid TumorChina
-
The First Affiliated Hospital of Guangdong Pharmaceutical...Guangzhou Anjie Biomedical Technology Co., Ltd.Unknown
-
Agenus Inc.Withdrawn
-
RenJi HospitalUnknown
-
Northwestern UniversityNational Cancer Institute (NCI)RecruitingLocally Advanced Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Anaplastic Carcinoma | Metastatic Thyroid Gland Oncocytic CarcinomaUnited States
-
Agenus Inc.RecruitingMelanoma | Ovarian Cancer | Prostate Cancer | Non-small-cell Lung Cancer | Endometrial Cancer | Advanced Cancer | Angiosarcoma | Fibrolamellar Carcinoma | Colorectal Cancer Without Liver MetastasesUnited States
-
The First Affiliated Hospital of Guangdong Pharmaceutical...University of Technology, Sydney; Guangzhou Anjie Biomedical Technology Co....UnknownNon-small Cell Lung Cancer | Lung Neoplasm MalignantChina
-
Ningbo Cancer HospitalUnknownAdvanced Cancer | Solid Tumor, AdultChina
-
OncoC4, Inc.Avance Clinical; OncoC4 AU Pty LtdRecruitingMelanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Esophageal Cancer | Fallopian Tube Cancer | Non Small Cell Lung Cancer | Bile Duct Cancer | Bladder Cancer | Endometrial Cancer | Head and Neck Squamous Cell Carcinoma | Anal Cancer | Primary Peritoneal... and other conditionsAustralia